



RECEIVED
JAN 10 2002
TECH CENTER 1600/2900
68/1614
#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Lawrence J. Marnett, et al.
Serial No.: 09/924,082
Filed: August 7, 2001
For: Compositions And Methods For Detecting And Quantifying
Cox-2 Activity And Anandamide Metabolites
Group No. 1614
Attorney's Docket No. N-7362 RSM
Customer No. 23456

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION AFTER FILING AN APPLICATION
BUT BEFORE A REJECTION)

Box IDS
Assistant Commissioner for Patents
Washington, D.C. 20231

December 10, 2001

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and §1.98, applicants hereby submit an
Information Disclosure Statement for consideration by the Examiner.

I. List of Patents, Publications or other Information

The Patents, publications, or other information submitted for consideration by
the Office are listed on the PTO-1449(s), attached hereto.

II. Copies

Submitted herewith is a legible copy of

- (i) each U.S. and Foreign Patent;
- (ii) each publication or that portion which caused it to be listed;
and/or
- (iii) all other information or that portion which caused it to be listed.

III. Concise Explanation of Relevance

The attached documents, publications, and/or other information attached hereto are in the English language and do not require a statement of relevancy.

IV. Fees


The IDS is being filed under 37 C.F.R. §1.97(b); before the mailing date of a first action on the merits (37 C.F.R. §1.97(b)(3)). No fee or statement is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. §1.97(c) and charge our Deposit Account in the amount of \$180.00 as required by 37 C.F.R. §1.17(p).

V. Payment of Fees

No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition if necessary) and charge the appropriate fee to Deposit Account 23-0035.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit in the overpayment to Deposit Account 23-0035 for any additional fees required under 37 C.F.R. §1.16 or §1.17.



Richard S. Myers, Jr.
Registration No. 42,022
WADDEY & PATTERSON
A Professional Corporation
Customer No. 23456
ATTORNEY FOR APPLICANT


This attorney is located at our Nashville, Tennessee office and can be contacted directly at:


Richard S. Myers, Jr.
Waddey & Patterson
414 Union Street, Suite 2020
Bank of America Plaza
Nashville, TN 37219
(615) 242-2400

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this Information Disclosure Statement is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Box IDS, Assistant Commissioner for Patents, Washington, D.C. 20231, December 10, 2001.

Richard S. Myers, Jr.


Registration No. 42,022


Date

RECEIVED
JAN 10 2002
TECH CENTER 1600/2900
Page 1 of 3

Comparable to
Form PTO-1449

U.S. Department of Commerce
Patent & Trademark Office

Atty. Docket No.

Serial No.

N-7362 RSM

09/924,082

Customer No. 23456

Applicant


Lawrence J. Marnett, et al.

Filing Date

August 7, 2001

Group

1651



INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

| Examiner Initial | Document No. | Date | Name | Class | Subclass | Filing Date If Appropriate |
|------------------|--------------|--------------------|------------------|-------|----------|----------------------------|
| AA | 3,632,627 | January 4, 1972 | Gordon, et al. | | | |
| AB | 4,675,281 | June 23, 1987 | Lands, et al | | | |
| AC | 5,047,354 | September 10, 1991 | Foegh, et al. | | | |
| AD | 5,162,504 | November 10, 1992 | Horoszewicz | | | |
| AE | 5,459,239 | October 17, 1995 | O'Neill, et al. | | | |
| AF | 5,474,903 | December 12, 1995 | Huland | | | |
| AG | 5,475,021 | December 12, 1995 | Marnett, et al | | | |
| AH | 5,543,297 | August 6, 1996 | Cromlish, et al | | | |
| AI | 5,589,575 | December 31, 1996 | Cohen, et al. | | | |
| AJ | 5,700,654 | December 23, 1997 | Roberts et al | | | |
| AK | 5,731,343 | March 24, 1998 | Feng, et al. | | | |
| AL | 5,756,092 | May 26, 1998 | Michelet, et al. | | | |
| AM | 5,837,479 | November 17, 1998 | Young, et al. | | | |
| AN | 5,858,694 | January 12, 1999 | Piazza, et al. | | | |
| AO | 5,858,696 | January 12, 1999 | Roberts, et al. | | | |
| AP | 5,874,235 | February 23, 1999 | Chan, et al | | | |
| AQ | 5,891,622 | April 6, 1999 | Morrow, et al. | | | |
| AR | 5,945,675 | August 31, 1999 | Malins | | | |
| AS | 5,958,978 | September 28, 1999 | Yamazaki, et al. | | | |
| AT | 5,973,191 | October 26, 1999 | Marnett, et al. | | | |
| AU | 5,995,645 | November 30, 1999 | Soenksen, et al. | | | |
| AV | 5,999,843 | December 7, 1999 | Anbar | | | |
| AW | 6,045,773 | April 4, 2000 | Isakson, et al. | | | |
| AX | 6,107,049 | August 22, 2000 | Allard, et al. | | | |

MISCELLANEOUS DOCUMENTS

| | |
|----|--|
| AY | KALGUTAR, et al.; Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: Facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors; PNAS January 18, 2000; 97(2) 925-930. ✓ |
| AZ | KOZAK, et al.; Oxygenation of the Endocannabinoid, 2-Arachidonylglycerol, to Glycerol Prostaglandins by Cyclooxygenase-2; The Journal of Biological Chemistry October 27, 2000; 43:33744-33749. ✓ |
| BA | KOZAK, et al.; Amino Acid Determinants in Cyclooxygenase-2 Oxygenation of the Endocannabinoid 2-Arachidonylglycerol; JBP Papers in Press June 11, 2001 ✓ |
| BB | LANDS, et al.; Phospholipid precursors of prostaglandins; Biochem. Biophys. Acta 1968; 164:426-429. ✓ |
| BC | PRESCOTT; A thematic series on oxidation of lipids as a source of messengers; J.Biol. Chem.; 274:22901. ✓ |

Examiner:

Date Considered

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

